Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: Preparation, in vitro and in vivo evaluation

Journal of Controlled Release

Volumn 208, Issue , 2015, Pages 67-75

  He, Zhijian ^a   Schulz, Anita ^b,f   Wan, Xiaomeng ^a   Seitz, Joshua ^c,g   Bludau, Herdis ^b   Alakhova, Daria Y ^a   Darr, David B ^a   Perou, Charles M ^a   Jordan, Rainer ^b   Ojima, Iwao ^c   Kabanov, Alexander V ^a,d   Luxenhofer, Robert ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c STONY BROOK UNIVERSITY   (United States)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITÉ DE MONTPELLIER   (France)

^g California Institute for Biomedical Research   (United States)

Author keywords

Drug delivery; In vitro; In vivo LCC6; Multi drug resistance; Nanomedicine; Orthotopic tumor model; Paclitaxel; Poly(2 oxazoline); Taxoids

Indexed keywords

CELL CULTURE; MEDICAL NANOTECHNOLOGY; MICELLES; SOLUBILITY; TUMORS;

IN-VITRO; IN-VIVO; MULTIDRUG RESISTANCE; PACLITAXEL; POLY(2-OXAZOLINE)S; TAXOIDS; TUMOR MODELS;

DRUG DELIVERY;

ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; MICELLE; OXAZOLE DERIVATIVE; POLY(2-OXAZOLINE); TAXOID;

ANIMAL; BREAST NEOPLASMS; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; MEDICINAL CHEMISTRY; MICELLE; MOUSE; NUDE MOUSE; PARTICLE SIZE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MICE; MICE, NUDE; MICELLES; OXAZOLES; PARTICLE SIZE; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931829393     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.02.024     Document Type: Article

References (52)

1. M.D. Galsky, A. Dritselis, P. Kirkpatrick, and W.K. Oh Cabazitaxel Nat. Rev. Drug Discov. 9 2010 677 678
2. M.L. Huang, D. Ehre, Q. Jiang, C. Hu, K. Kirshenbaum, and M.D. Ward Biomimetic peptoid oligomers as dual-action antifreeze agents Proc. Natl. Acad. Sci. U. S. A. 109 2012 19922 19927
3. L.M. Zasadil, K.A. Andersen, D. Yeum, G.B. Rocque, L.G. Wilke, A.J. Tevaarwerk, R.T. Raines, M.E. Burkard, and B.A. Weaver Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles Sci. Transl. Med. 6 2014 229ra43
4. R.T. Liggins, W.L. Hunter, and H.M. Burt Solid-state characterization of paclitaxel J. Pharm. Sci. 86 1997 1458 1463
5. K.L. Hennenfent, and R. Govindan Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 17 2006 735 749
6. U. Vanhoefer, S. Cao, A. Harstrick, S. Seeber, and Y.M. Rustum Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) Ann. Oncol. 8 1997 1221 1228
7. S.C. Lee, C. Kim, I.C. Kwon, H. Chung, and S.Y. Jeong Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(epsilon-caprolactone) copolymer as a carrier for paclitaxel J. Control. Release 89 2003 437 446
8. M. Wada, H. Jinno, M. Ueda, T. Ikeda, M. Kitajima, T. Konno, J. Watanabe, and K. Ishihara Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel Anticancer Res. 27 2007 1431 1435
9. D.F. Hayes, A.D. Thor, L.G. Dressler, D. Weaver, S. Edgerton, D. Cowan, G. Broadwater, L.J. Goldstein, S. Martino, J.N. Ingle, I.C. Henderson, L. Norton, E.P. Winer, C.A. Hudis, M.J. Ellis, and D.A. Berry HER2 and response to paclitaxel in node-positive breast cancer N. Engl. J. Med. 357 2007 1496 1506
10. L.E. van Vlerken, Z. Duan, S.R. Little, M.V. Seiden, and M.M. Amiji Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model Mol. Pharm. 5 2008 516 526
11. M.G. Carstens, P.H. de Jong, C.F. van Nostrum, J. Kemmink, R. Verrijk, L.G. de Leede, D.J. Crommelin, and W.E. Hennink The effect of core composition in biodegradable oligomeric micelles as taxane formulations Eur. J. Pharm. Biopharm. 68 2008 596 606
12. M.L. Forrest, J.A. Yáñez, C.M. Remsberg, Y. Ohgami, G.S. Kwon, and N.M. Davies Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity Pharm. Res. 25 2008 194 206
13. H.C. Shin, A.W. Alani, D.A. Rao, N.C. Rockich, and G.S. Kwon Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs J. Control. Release 140 2009 294 300
14. R. Luxenhofer, A. Schulz, C. Roques, S. Li, T.K. Bronich, E.V. Batrakova, R. Jordan, and A.V. Kabanov Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs Biomaterials 31 2010 4972 4979
15. N. Kolishetti, S. Dhar, P.M. Valencia, L.Q. Lin, R. Karnik, S.J. Lippard, R. Langer, and O.C. Farokhzad Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy Proc. Natl. Acad. Sci. U. S. A. 107 2010 17939 17944
16. W. Zhang, Y. Shi, Y. Chen, J. Ye, X. Sha, and X. Fang Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors Biomaterials 32 2011 2894 2906
17. H.C. Shin, A.W.G. Alani, H. Cho, Y. Bae, J.M. Kolesar, and G.S. Kwon A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs Mol. Pharm. 8 2011 1257 1265
18. D. Yang, S. Van, X. Jiang, and L. Yu Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)-paclitaxel nanoparticles Int. J. Nanomedicine 6 2011 85 91
19. J. Seitz, and I. Ojima Drug conjugates with polyunsaturated fatty acids F. Kratz, P. Senter, H. Steinhagen, Drug Delivery in Oncology 2011 Wiley-VCH Verlag GmbH & Co. KGaA Weinheim, Germany 1323 1357
20. J. Hrkach, D. Von Hoff, M.M. Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J.J. Song, Y.H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, P.W. Kantoff, N.H. Bander, C. Sweeney, O.C. Farokhzad, R. Langer, and S. Zale Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 4 2012 128ra39
21. Y. Han, Z. He, A. Schulz, T.K. Bronich, R. Jordan, R. Luxenhofer, and A.V. Kabanov Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles Mol. Pharm. 9 2012 2302 2313
22. A. Schulz, S. Jaksch, R. Schubel, E. Wegener, Z. Di, Y. Han, A. Meister, J. Kressler, A.V. Kabanov, R. Luxenhofer, C.M. Papadakis, and R. Jordan Drug-induced morphology switch in drug delivery systems based on poly(2-oxazoline)s ACS Nano 8 2014 2686 2696
23. N.P. Desai, V. Trieu, L.Y. Hwang, R. Wu, P. Soon-Shiong, and W.J. Gradishar Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status Anticancer Drugs 19 2008 899 909
24. T.Y. Kim, D.W. Kim, J.Y. Chung, S.G. Shin, S.C. Kim, D.S. Heo, N.K. Kim, and Y.J. Bang Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin. Cancer Res. 10 2004 3708 3716
25. T. Hamaguchi, Y. Matsumura, M. Suzuki, K. Shimizu, R. Goda, I. Nakamura, I. Nakatomi, M. Yokoyama, K. Kataoka, and T. Kakizoe NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Br. J. Cancer 92 2005 1240 1246
26. H.S. Rugo, W.T. Barry, A. Moreno-Aspitia, A.P. Lyss, C. Cirrincione, E. Mayer, M. Naughton, R.M. Layman, L.A. Carey, R.A. Somer, E.A. Perez, C. Hudis, and E.P. Winer CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) J. Clin. Oncol. 30 2012 CRA 1002
27. I. Ojima, and M. Das Recent advances in the chemistry and biology of new generation taxoids J. Nat. Prod. 72 2009 554 565
28. R. Matesanz, C. Trigili, J. Rodríguez-Salarichs, I. Zanardi, B. Pera, A. Nogales, W.-S. Fang, J. Jímenez-Barbero, Á. Canales, I. Barasoain, I. Ojima, and J.F. Díaz Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances Bioorg. Med. Chem. 22 2014 5078 5090
29. I. Ojima, J. Chen, L. Sun, C.P. Borella, T. Wang, M.L. Miller, S. Lin, X. Geng, L. Kuznetsova, and C. Qu Design, synthesis, and biological evaluation of new-generation taxoids J. Med. Chem. 51 2008 3203 3221
30. M. Barz, R. Luxenhofer, R. Zentel, and M.J. Vicent Overcoming the PEG addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics Polym. Chem. 2 2011 1900 1918
31. R. Luxenhofer, Y. Han, A. Schulz, J. Tong, Z. He, A.V. Kabanov, and R. Jordan Poly(2-oxazoline)s as polymer therapeutics Macromol. Rapid Commun. 33 2012 1613 1631
32. O. Sedlacek, B.D. Monnery, S.K. Filippov, R. Hoogenboom, and M. Hruby Poly (2-oxazoline) s - are they more advantageous for biomedical applications than other polymers? Macromol. Rapid Commun. 33 2012 1648 1662
33. N. Zhang, T. Pompe, I. Amin, R. Luxenhofer, C. Werner, and R. Jordan Tailored polymer brushes of poly(2-oxazoline)s to control the protein adsorption and cell adhesion Macromol. Biosci. 7 2012 926 936
34. J. Tong, X. Yi, R. Luxenhofer, W.A. Banks, R. Jordan, M.C. Zimmerman, and A.V. Kabanov Conjugates of superoxide dismutase 1 with amphiphilic poly(2-oxazoline) block copolymers for enhanced brain delivery: synthesis, characterization and evaluation in vitro and in vivo Mol. Pharm. 10 2013 360 377
35. K.L. Eskow Jaunarajs, D.G. Standaert, T.X. Viegas, M.D. Bentley, Z. Fang, B. Dizman, K. Yoon, R. Weimer, P. Ravenscroft, T.H. Johnston, M.P. Hill, J.M. Brotchie, and R.W. Moreadith Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit Mov. Disord. 28 2013 1675 1682
36. R.W. Moreadith 248th ACS National Meeting and Exhibition 2014
37. F. Leonessa, D. Green, T. Licht, A. Wright, K. Wingate-Legette, J. Lippman, M.M. Gottesman, and R. Clarke MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer Br. J. Cancer 73 1996 154 161
38. D.J. Jerry, F.S. Kittell, C. Kuperwasser, R. Laucirica, E.S. Dickinson, P.J. Bonilla, J.S. Butel, and D. Medina A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development Oncogene 19 2000 1052 1058
39. J.I. Herschkowitz, W. Zhao, M. Zhang, J. Usary, G. Murrow, D. Edwards, J. Knezevic, S.B. Greene, D. Darr, M.A. Troester, S.G. Hilsenbeck, D. Medina, C.M. Perou, and J.M. Rosen Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells Proc. Natl. Acad. Sci. U. S. A. 109 2012 2778 2783
40. T. Hamaguchi, K. Kato, H. Yasui, C. Morizane, M. Ikeda, H. Ueno, K. Muro, Y. Yamada, T. Okusaka, K. Shirao, Y. Shimada, H. Nakahama, and Y. Matsumura A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation Br. J. Cancer 97 2007 170 176
41. K. Kato, K. Chin, T. Yoshikawa, K. Yamaguchi, Y. Tsuji, T. Esaki, K. Sakai, M. Kimura, T. Hamaguchi, Y. Shimada, Y. Matsumura, and R. Ikeda Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer Invest. New Drugs 30 2012 1621 1627
42. F. Gu, L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno, R. Langer, and O.C. Farokhzad Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers Proc. Natl. Acad. Sci. U. S. A. 105 2008 2586 2591
43. A. Schulz, Y. Han, Z. He, T.K. Bronich, A.V. Kabanov, R. Luxenhofer, and R. Jordan Poly(2-oxazoline)s as high-capacity multi-drug delivery systems Polym. Prepr. 53 2012 305
44. F.C. Gaertner, R. Luxenhofer, B. Blechert, R. Jordan, and M. Essler Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s J. Control. Release 119 2007 291 300
45. R. Luxenhofer, G. Sahay, A. Schulz, D. Alakhova, T.K. Bronich, R. Jordan, and A.V. Kabanov Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles J. Control. Release 153 2011 73 82
46. J. Kronek, Z. Kroneková, J. Lustoň, E. Paulovičová, L. Paulovičová, and B. Mendrek In vitro bio-immunological and cytotoxicity studies of poly(2-oxazolines) J. Mater. Sci. Mater. Med. 22 2011 1725 1734
47. M. Bauer, C. Lautenschlaeger, K. Kempe, L. Tauhardt, U.S. Schubert, and D. Fischer Poly(2-ethyl-2-oxazoline) as alternative for the stealth polymer poly(ethylene glycol): comparison of in vitro cytotoxicity and hemocompatibility Macromol. Biosci. 12 2012 986 998
48. M. Bauer, S. Schroeder, L. Tauhardt, K. Kempe, U.S. Schubert, and D. Fischer In vitro hemocompatibility and cytotoxicity study of poly (2-methyl-2-oxazoline) for biomedical applications J. Polym. Sci. A Polym. Chem. 51 2013 1816 1821
49. H.J. Kloosterboer, G.H. Deckers, W.G. Schoonen, R.G. Hanssen, U.M. Rose, P.M. Verbost, J.G. Hsiu, R.F. Williams, and G.D. Hodgen Preclinical experience with two selective progesterone receptor modulators on breast and endometrium Steroids 65 2000 733 740
50. P. Jiang, R. Mukthavaram, Y. Chao, N. Nomura, I.S. Bharati, V. Fogal, S. Pastorino, D. Teng, X. Cong, S.C. Pingle, S. Kapoor, K. Shetty, A. Aggrawal, S. Vali, T. Abbasi, S. Chien, and S. Kesari In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells Br. J. Cancer 111 2014 1562 1571
51. L. Zhang, P. Marrano, S. Kumar, M. Leadley, E. Elias, P. Thorner, and S. Baruchel Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors Clin. Cancer Res. 19 2013 5972 5983
52. P.J. Roberts, J.E. Usary, D.B. Darr, P.M. Dillon, A.D. Pfefferle, M.C. Whittle, J.S. Duncan, S.M. Johnson, A.J. Combest, J. Jin, W.C. Zamboni, G.L. Johnson, C.M. Perou, and N.E. Sharpless Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models Clin. Cancer Res. 18 2012 5290 5303